The journey of MASLD: Tracking resolution, relapse, and predictive factors after sleeve gastrectomy and one-anastomosis gastric bypass, a propensity score-matched cohort study.
{"title":"The journey of MASLD: Tracking resolution, relapse, and predictive factors after sleeve gastrectomy and one-anastomosis gastric bypass, a propensity score-matched cohort study.","authors":"Sara Sadeghi, Farhad Hosseinpanah, Alireza Khalaj, Maryam Mahdavi, Majid Valizadeh, Hamidreza Taheri, Maryam Barzin","doi":"10.1016/j.diabres.2024.111969","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To assess the rates and predictors of resolution and relapse of metabolic-dysfunction associated steatotic liver disease (MASLD) in individuals undergoing sleeve gastrectomy (SG) or one-anastomosis gastric bypass (OAGB).</p><p><strong>Methods: </strong>This observational prospective cohort study involved 1618 propensity score-matched participants (81.5% female) with concurrent MASLD and obesity who underwent SG or OAGB between 2013 and 2023.</p><p><strong>Results: </strong>In the context of a maximum follow-up of four years with a median follow-up of 2.2 years (IQR: 1.0-3.3), the overall rates of MASLD resolution and relapse were 71.1 per 1000 person-month and 8.7 per 1000 person-month, respectively. These rates were comparable between the SG and OAGB groups. Significant resolution predictors were a lower percentage of hepatic steatosis, a higher percentage of 12-month excess weight loss (EWL%), and younger age. In contrast, an increased percentage of liver steatosis, a higher pre-operative (Pre-Op) fat mass percentage (FM%), and older age were significant predictors of relapse.</p><p><strong>Conclusion: </strong>This study found no significant differences in MASLD resolution and relapse rates between SG and OAGB. Key factors influencing MASLD outcomes included the percentage of hepatic steatosis, 12-month EWL%, Pre-Op FM%, and age.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"111969"},"PeriodicalIF":6.1000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.diabres.2024.111969","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: To assess the rates and predictors of resolution and relapse of metabolic-dysfunction associated steatotic liver disease (MASLD) in individuals undergoing sleeve gastrectomy (SG) or one-anastomosis gastric bypass (OAGB).
Methods: This observational prospective cohort study involved 1618 propensity score-matched participants (81.5% female) with concurrent MASLD and obesity who underwent SG or OAGB between 2013 and 2023.
Results: In the context of a maximum follow-up of four years with a median follow-up of 2.2 years (IQR: 1.0-3.3), the overall rates of MASLD resolution and relapse were 71.1 per 1000 person-month and 8.7 per 1000 person-month, respectively. These rates were comparable between the SG and OAGB groups. Significant resolution predictors were a lower percentage of hepatic steatosis, a higher percentage of 12-month excess weight loss (EWL%), and younger age. In contrast, an increased percentage of liver steatosis, a higher pre-operative (Pre-Op) fat mass percentage (FM%), and older age were significant predictors of relapse.
Conclusion: This study found no significant differences in MASLD resolution and relapse rates between SG and OAGB. Key factors influencing MASLD outcomes included the percentage of hepatic steatosis, 12-month EWL%, Pre-Op FM%, and age.
期刊介绍:
Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.